Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: Webster Groves who wrote (56252)	10/11/2009 4:01:44 PM
From: energyplay	Read Replies (1) \| Respond to of 217943

I will basically agree with your statement about the EU pushing their own agenda. One major disagreement - I see the NIH work as valuble - Much of NIH work eventually is used to creaste new drugs. Prescritptions drugs are a 300 Billion industry in the US, the the drug companies run over 50 Billion in R&D. Many drug companies are profitably enough that they pay a good slice of taxes, and their employees are paid enough to make good tax contribution too. Actual benefits of the durgs and proceedures can have postie economic value - reducing heart attacks being one obvious example. The NIH recieved a massive ramp in size during the Clinton years, and this is starting to pay off. The one major industrial R&D lab left are the three IBM labs, and San Jose and Zurich did most of the leading edge work. They have large patent revenue streams.